FdaApplication
NDA 216962
Identifiers
- fda_app_no: NDA216962
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2024-10-16 |
Revenue by product
VYALEV
| Period | Revenue |
|---|---|
| Q2 2026 | $256.0M* |
| Q1 2026 | $201.0M* |
| Q4 2025 | $183.0M* |
| Q3 2025 | $138.0M* |
| Q2 2025 | $98.0M* |
| Q1 2025 | $63.0M* |
| Q4 2024 | $44.0M* |
| Q3 2024 | $28.0M* |
| Q2 2024 | $18.0M* |
| Q1 2024 | $9.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VYALEV | FOSCARBIDOPA; FOSLEVODOPA | 120MG/10ML;2400MG/10ML (12MG/ML | SOLUTION;SUBCUTANEOUS |
1 product